Northwest CEO gave 'conflicting language' on timeline, Feuerstein says The CEO of Northwest Biotherapeutics, Linda Powers, offered "conflicting language" yesterday regarding the timeline for enrollment of 312 glioblastoma patients in the phase III study of the experimental cancer vaccine DC-Vax, The Street's Adam Feuerstein writes. Reference Link
Northwest Biotherapeutics files to delay Form 10-K The company requires additional time to complete its year end procedures. Those procedures could not be completed without incurring undue hardship and expense. The company undertakes the responsibility to file such annual report no later than fifteen days after its original date.